Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product

被引:51
作者
El-Bagary, Ramzia I. [1 ]
Elkady, Ehab F. [1 ]
Ayoub, Bassam M. [1 ]
机构
[1] Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo 11562, Egypt
关键词
Sitagliptin phosphate; Metformin; Reversed-phase liquid chromatography; Stability indicating assay; Pharmaceutical preparation; TANDEM MASS-SPECTROMETRY; INHIBITOR SITAGLIPTIN; DPP-4; INHIBITOR; HUMAN PLASMA; PHARMACOKINETICS; EXTRACTION;
D O I
10.1016/j.talanta.2011.04.051
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Two reversed-phase liquid chromatographic (RP-LC) methods have been developed for the determination of sitagliptin phosphate monohydrate (STG). The first method comprised the determination of STG alone in bulk and plasma; and in its pharmaceutical preparation. This method was based on isocratic elution of STG using a mobile phase consisting of potassium dihydrogen phosphate buffer pH (7.8)-acetonitrile (70:30, v/v) at a flow rate of 1 mLmin(-1) with flourometric detection. The flourometric detector was operated at 267 nm for excitation and 575 nm for emission. In the second method, the simultaneous determination of SIC and metformin (MET) in the presence of sitagliptin alkaline degradation product (SDP) has been developed. In this method, the ternary mixture of STG. MET and SDP was separated using a mobile phase consisting of potassium dihydrogen phosphate buffer pH (4.6)-acetonitrile-methanol (30:50:20, v/v/v) at a flow rate of 1 mL min(-1) with UV detection at 220 nm. Chromatographic separation in the two methods was achieved on a Symmetry (R) Waters C(18) column (150 mm x 4.6 mm, 5 mu m). Linearity, accuracy and precision were found to be acceptable over the concentration ranges of 0.25-200 mu g mL(-1) for STG with the first method and 5-160 mu g mL(-1), 25-800 mu g mL(-1) for STG and MET, respectively with the second method. The optimized methods were validated and proved to be specific, robust and accurate for the quality control of the cited drugs in pharmaceutical preparations. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:673 / 680
页数:8
相关论文
共 16 条
[1]  
Ali AR, 2009, J AOAC INT, V92, P119
[2]  
[Anonymous], 2007, US PHARM 30 NAT FORM, P249
[3]  
[Anonymous], 1996, Indian Pharmacopoeia, VI, P469
[4]   Review of sitagliptin phosphate: a novel treatment for type 2 diabetes [J].
Gallwitz, Baptist .
VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (02) :203-210
[5]   First generation process for the preparation of the DPP-IV inhibitor sitagliptin [J].
Hansen, KB ;
Balsells, J ;
Dreher, S ;
Hsiao, Y ;
Kubryk, M ;
Palucki, M ;
Rivera, N ;
Steinhuebel, D ;
Armstrong, JD ;
Askin, D ;
Grabowski, EJJ .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2005, 9 (05) :634-639
[6]   Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects [J].
Herman, Gary A. ;
Bergman, Arthur ;
Liu, Fang ;
Stevens, Cathy ;
Wang, Amy Q. ;
Zeng, Wei ;
Chen, Li ;
Snyder, Karen ;
Hilliard, Deborah ;
Tanen, Michael ;
Tanaka, Wesley ;
Meehan, Alan G. ;
Lasseter, Kenneth ;
Dilzer, Stacy ;
Blum, Robert ;
Wagner, John A. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (08) :876-886
[7]  
MOFFAT AC, 2004, CLARKES ANAL DRUGS P, P797
[8]   Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction [J].
Nirogi, Ramakrishna ;
Kandikere, Vishwottarn ;
Mudigonda, Koteshwara ;
Komarneni, Prashanth ;
Aleti, Raghupathi ;
Boggavarapu, Rajeshkumar .
BIOMEDICAL CHROMATOGRAPHY, 2008, 22 (02) :214-222
[9]   HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies [J].
Porta, Valentina ;
Schramm, Simone Grigoleto ;
Kano, Eunice Kazue ;
Koono, Eunice Emiko ;
Armando, Yara Popst ;
Fukuda, Kazuo ;
dos Reis Serra, Cristina Helena .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 46 (01) :143-147
[10]  
Rizk M, 2000, Pharm Acta Helv, V74, P371, DOI 10.1016/S0031-6865(00)00025-X